Oncotarget

Research Papers:

Necdin modulates leukemia-initiating cell quiescence and chemotherapy response

Chonghua Yao, Michihiro Kobayashi, Sisi Chen, Sarah C. Nabinger, Rui Gao, Stephen Z. Liu, Takashi Asai and Yan Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:87607-87622. https://doi.org/10.18632/oncotarget.20999

Metrics: PDF 1446 views  |   HTML 2647 views  |   ?  


Abstract

Chonghua Yao1,*, Michihiro Kobayashi2,*, Sisi Chen3, Sarah C. Nabinger2, Rui Gao2, Stephen Z. Liu2, Takashi Asai4 and Yan Liu2,3

1Department of Rheumatism, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

2Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA

3Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

4Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

*Co-first authors, These authors have contributed equally to this work

Correspondence to:

Yan Liu, email: [email protected]

Keywords: Necdin, leukemia-initiating cells, quiescence, MLL-AF9, chemotherapy

Received: March 13, 2017    Accepted: August 26, 2017    Published: September 18, 2017

ABSTRACT

Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease after a period of latency. While we demonstrated that p53 target gene Necdin maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and response to chemotherapy are unclear. In this study, we utilized two well-established murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the number of functional LICs and enhanced myeloid differentiation in vivo, leading to delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, manifested by decreased viability and enhanced apoptosis. We observed decreased expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin null leukemia cells following chemotherapy treatment, indicating that p53-dependent apoptotic pathways may be activated in the absence of Necdin. In addition, we found that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem and progenitor cells in transplantation assays. However, Necdin-deficiency did not affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response in a context-dependent manner. Our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20999